natgillin/translations-raw huggingface dataset:
Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with aripiprazole and preventive measures undertaken (see section 4.8). 
Budući da bolesnici liječeni antipsihoticima često već imaju stečene čimbenike rizika za VTE, prije i tijekom liječenja aripiprazolom moraju se utvrditi svi mogući čimbenici rizika za VTE i poduzeti preventivne mjere (vidjeti dio 4.8).
Aripiprazole is well absorbed when administered orally as the solution. 
Aripiprazol se dobro apsorbira kada se primjenjuje u obliku oralne otopine.
Based on results from trials with oral administration of aripiprazole, aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 L/kg, indicating extensive extravascular distribution. 
Prema rezultatima iz ispitivanja oralno primijenjenog aripiprazola, aripiprazol se opsežno raspodjeljuje po cijelom tijelu uz prividan volumen raspodjele od 4,9 l/kg, koji ukazuje na opsežnu ekstravaskularnu raspodjelu.
Patients were 7 to 17 years of age and presented an average score of 30 on Total Tic Score on the Yale Global Tic Severity Scale (TTS-YGTSS) at baseline. 
Bolesnici su bili u dobi od 7 do 17 godina i imali su prosječno 30 bodova na početku ispitivanja za ukupni zbroj tikova na Yaleovoj općoj ljestvici težine tikova (engl.
An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 mg/kg/day to 125 mg/kg/day (1 to 3 times the mean steady-state AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg/m2). 
Dodatni nalaz bio je kolelitijaza kao posljedica precipitacije sulfatnih konjugata hidroksi metabolita aripiprazola u žuči majmuna nakon ponovljenih peroralnih doza od 25 mg/kg/dan do 125 mg/kg/dan (1 do 3 puta veća od srednje vrijednosti AUC-a u stanju dinamičke ravnoteže pri maksimalnoj preporučenoj kliničkoj dozi ili 16 do 81 puta veća od maksimalne preporučene doze za ljude temeljene na mg/m2).
Yellow iron oxide (E 172) 
žuti željezov oksid (E 172)
The oral solution contains fructose and sucrose. 
Oralna otopina sadrži fruktozu i saharozu.
• other anti-depressants (such as venlafaxine and tryptophan) used in major depression 
• drugi antidepresivi (kao što su venlafaksin i triptofan) koji se primjenjuju kod velike depresije
ABILIFY contains aspartame 
ABILIFY sadrži aspartam
These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 mg/kg/day to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose). 
Oni su uključivali adrenokortikalnu toksičnost ovisnu o dozi (akumulacija pigmenta lipofuscina i/ili gubitak stanica parenhima) u štakora nakon 104 tjedna primjene doze od 20 mg/kg/dan do 60 mg/kg/dan (3 do 10 puta veća od srednje vrijednosti AUC-a u stanju dinamičke ravnoteže pri maksimalnoj preporučenoj dozi za ljude) i povišenu učestalost adrenokortikalnih karcinoma te kombinaciju adrenokortikalnih adenoma/karcinoma u ženki štakora koje su primale dozu od 60 mg/kg/dan (10 puta veća od srednje vrijednosti AUC-a u stanju dinamičke ravnoteže pri maksimalnoj preporučenoj dozi za ljude).
The ABILIFY solution for injection is a clear, colourless, aqueous solution. 
ABILIFY otopina za injekciju je bistra, bezbojna, vodena otopina.
• high blood pressure, 
• visoki krvni tlak, • nesvjestica,
• antifungal medicines (such as ketoconazole, itraconazole) 
• lijekove za liječenje gljivičnih infekcija (kao što su ketokonazol, itrakonazol)
Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. 
Patološko kockanje i drugi poremećaji kontrole nagona Bolesnici mogu osjetiti pojačane porive, osobito za kockanjem, te nemogućnost kontroliranja tih poriva dok uzimaju aripiprazol.
• hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, 
• situacije u kojima bolesnik čuje, vidi ili osjeća stvari kojih nema, sumnjičavost, pogrešno vjerovanje, nepovezan govor i ponašanje te emocionalna tupost.
If you take more ABILIFY than you should 
Ako uzmete više lijeka ABILIFY nego što ste trebali
The most commonly reported adverse reactions in placebo-controlled trials were akathisia and nausea each occurring in more than 3 % of patients treated with oral aripiprazole. 
Najčešće prijavljene nuspojave u placebom kontroliranim ispitivanjima bile su akatizija i mučnina, od kojih se svaka javlja u više od 3 % bolesnika liječenih oralnim aripiprazolom.
• combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness and sudden changes in blood pressure and heart rate, fainting (neuroleptic malignant syndrome), 
• kombinacija vrućice, ukočenosti mišića, ubrzanog disanja, znojenja, smanjene svijesti i iznenadnih promjena krvnog tlaka i brzine otkucaja srca, nesvjestica (neuroleptički maligni sindrom)
A vial contains 9.75 mg (1.3 mL) aripiprazole. 
Bočica sadrži 9,75 mg (1,3 ml) aripiprazola.
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
PRILOG II A. PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET
Aripiprazole was superior to placebo in change from baseline at week 4 and at week 12 on the Y-MRS total score. 
Aripiprazol je bio superioran u odnosu na placebo kada je u pitanju promjena ukupnog YMRS rezultata u 4. i 12. tjednu u odnosu na početnu vrijednost.
• nervousness, 
• nervoza,
Four mood stabilizer subgroups were assessed in the randomised phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo + valproate. 
Četiri podskupine stabilizatora raspoloženja su se procjenjivale u randomiziranoj fazi: aripiprazol + litij, aripiprazol
In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52-weeks was similar in both groups (oral aripiprazole 77 % and haloperidol 73 %). 
U haloperidolom kontroliranom ispitivanju, udio bolesnika u kojih se održao terapijski odgovor na lijek do 52. tjedna ispitivanja bio je sličan u obje skupine (oralni aripiprazol 77 % i haloperidol 73 %).
Each carton contains one bottle and both a calibrated polypropylene measuring cup and a calibrated polypropylene low-density polyethylene dropping pipette. 
Jedna kutija sadrži jednu bocu te kalibriranu polipropilensku odmjernu čašicu i kalibriranu kapaljku od polipropilena i polietilena male gustoće.
• swelling of hands, ankles or feet, 
• bol u prsištu, • oticanje šaka, gležnjeva ili stopala,
Similarly, for dehydro-aripiprazole the geometric means of Cmax and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with aripiprazole alone. 
Slično tome, geometrijski određena srednja vrijednost Cmax dehidro-aripiprazola nakon zajedničke primjene s karbamazepinom bila je manja za 69 %, a AUC-a za 71 % od onih nakon liječenja samo aripiprazolom.
If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8). 
Ako se u bolesnika koji uzima aripiprazol pojave znakovi i simptomi tardivne diskinezije, mora se razmotriti smanjenje doze ili prekid terapije (vidjeti dio 4.8).
If you forget to take ABILIFY 
Ako ste zaboravili uzeti ABILIFY
- binge eating (eating large amounts of food in a short time period) or compulsive eating 
- prejedanje (jedenje ogromnih količina hrane u kratkom razdoblju) ili kompulzivno jedenje (jedenje veće količine hrane nego što je normalno i više nego je potrebno za utaženje gladi), - sklonost da se odluta.
• anticonvulsants used to treat epilepsy (such as carbamazepine, phenytoin, phenobarbital) 
• antikonvulzive koji se primjenjuju za liječenje epilepsije (kao što su karbamazepin, fenitoin,
• The other ingredients are disodium edetate, fructose, glycerin, lactic acid, methyl parahydroxybenzoate (E218), propylene glycol, propyl parahydroxybenzoate (E216), sodium hydroxide, sucrose, purified water, and orange flavour. 
• Drugi sastojci su dinatrijev edetat, fruktoza, glicerin, laktatna kiselina, metilparahidroksibenzoat (E 218), propilenglikol, propilparahidroksibenzoat (E 216), natrijev hidroksid, saharoza,
ABILIFY solution for injection is for intramuscular use. 
ABILIFY otopina za injekciju namijenjena je za intramuskularnu primjenu.
ABILIFY is effective in a dose range of 10 mg/day to 30 mg/day (i.e. 10 mL to 30 mL solution/day). 
ABILIFY je učinkovit u rasponu doza od 10 mg/dan do 30 mg/dan (tj. 10 ml do 30 ml otopine/dan).
In a relative bioavailability study comparing the pharmacokinetics of 30 mg aripiprazole as the oral solution to 30 mg aripiprazole tablets in healthy subjects, the solution to the tablet ratio of geometric mean Cmax values was 122 % (n = 30). 
U ispitivanju relativne bioraspoloživosti, u kojem se farmakokinetika 30 mg aripiprazola primijenjena u obliku oralne otopine uspoređivala s onom kada je aripiprazol promijenjen u dozi od 30 mg u obliku tableta u zdravih ispitanika, omjer geometrijskih srednjih vrijednosti Cmax između otopine i tableta iznosio je 122 % (n = 30).
ABILIFY is for oral use. 
ABILIFY je namijenjen za peroralnu primjenu.
In the pooled trials, the incidence of low serum prolactin levels in females (< 3 ng/mL) and males (< 2 ng/mL) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively. 
U objedinjenim je ispitivanjima incidencija niske razine prolaktina u serumu u djevojčica (< 3 ng/ml) liječenih aripiprazolom iznosila 27/46 (58,7 %), a u dječaka (< 2 ng/ml) 258/298 (86,6 %).
• uncontrollable twitching, jerking or writhing movements, restless legs, 
• nekontrolirano trzanje mišića, trzajni ili savijajući pokreti, nemirne noge,
In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56 to 99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo. 
82,4 godine; raspon: 56 do 99 godina) s psihozom koja je bila povezana s Alzheimerovom bolešću, bolesnici liječeni aripiprazolom imali su povišen rizik od smrti u odnosu na bolesnike koji su primali placebo.
Aripiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8). 
Aripiprazol malo do umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima zbog mogućih učinaka na živčani i vidni sustav, kao što su sedacija, somnolencija, sinkopa, zamagljen vid,
• skin rash, 
• kožni osip,
Irritability associated with autistic disorder in paediatric patients (see section 4.2) Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible-dose (2 mg/day to 15 mg/day) and one fixed-dose (5 mg/day, 10 mg/day, or 15 mg/day)] and in one 52-week open-label trial. 
Aripiprazol se ispitivao u bolesnika u dobi od 6 do 17 godina u dva placebom kontrolirana ispitivanja u trajanju od 8 tjedana [jedno s fleksibilnom dozom (2 mg/dan do 15 mg/dan), drugo s fiksnom dozom (5 mg/dan, 10 mg/dan ili 15 mg/dan)] i jednom otvorenom ispitivanju u trajanju od 52 tjedna.
In clinical studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan). 
U kliničkim ispitivanjima, doze aripiprazola od 10 mg/dan do 30 mg/dan nisu imale značajnog učinka na metabolizam supstrata CYP2D6 (omjer dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin), CYP2C19 (omeprazol) ni CYP3A4 (dekstrometorfan).
Population pharmacokinetic evaluation showed no evidence of race-related differences on the pharmacokinetics of aripiprazole. 
Rasa Populacijska farmakokinetička procjena nije dala nikakve dokaze da postoje razlike povezane s rasom u farmakokinetici aripiprazola.
In a 52-week, placebo-controlled trial, in patients with a current manic or mixed episode of Bipolar I Disorder who achieved sustained remission (Young Mania Rating Scale [YMRS] and MADRS with total scores ≤ 12) on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for 12 consecutive weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46 % decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65 % decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to demonstrate superiority over placebo in preventing recurrence into depression. 
Young Mania Rating Scale, YMRS] i MADRS ≤ 12) s aripiprazolom (10 mg/dan do 30 mg/dan) kao adjuvantnom terapijom uz litij ili valproat tijekom 12 uzastopnih tjedana, adjuvantna terapija aripiprazolom pokazala je nadmoć u odnosu na placebo sa 46 %-tnim smanjenjem rizika (omjer hazarda je 0,54) u prevenciji ponavljanja bipolarnog poremećaja i sa 65 %-tnim smanjenjem rizika (omjer hazarda je 0,35) u prevenciji ponavljanja maničnog poremećaja u odnosu na adjuvantnu terapiju placebom, ali nije uspjela pokazati nadmoć u odnosu na placebo u prevenciji ponavljanja depresije.
strong impulse to gamble excessively despite serious personal or family consequences altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive uncontrollable excessive shopping binge eating (eating large amounts of food in a short time period) or compulsive eating 
- snažan nagon za pretjeranim kockanjem usprkos ozbiljnim posljedicama za osobu ili obitelj, - promijenjen ili povećan seksualni interes i ponašanje koje znatno zabrinjava Vas ili druge, na primjer, povećani seksualni poriv,
Oral solution Clear, colourless to light yellow liquid solution. 
Bistra, bezbojna do svijetložuta tekućina.
Manic episodes in Bipolar I Disorder: the recommended starting dose for ABILIFY is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1). 
Manične epizode u bipolarnom poremećaju tipa I: preporučena početna doza za ABILIFY je 15 mg i primjenjuje se jedanput dnevno neovisno o obrocima u obliku monoterapije ili kombinirane terapije (vidjeti dio 5.1).
Thus, aripiprazole is unlikely to cause clinically important medicinal product interactions mediated by these enzymes. 
CYP1A2 pa stoga nije vjerojatno da će aripiprazol prouzročiti klinički važne interakcije s drugim lijekovima koji se metaboliziraju putem navedenih enzima.
Urinary incontinence Urinary retention 
Poremećaji bubrega i mokraćnog sustava urinarna inkontinencija retencija urina
In clinical trials of treatment with oral aripiprazole, the incidence of QT prolongation was comparable to placebo. 
U kliničkim ispitivanjima liječenja peroralnim aripiprazolom, incidencija produljenja QT intervala bila je usporediva s placebom.
• triptans, tramadol and tryptophan used for conditions including depression, generalised anxiety disorder, obsessive compulsive disorder (OCD) and social phobia as well as migraine and pain 
• triptani, tramadol i triptofan koji se primjenjuju u stanjima koja uključuju depresiju, generalizirani anksiozni poremećaj, opsesivno kompulzivni poremećaj (OKP) i socijalnu fobiju,
Package leaflet: Information for the user ABILIFY 10 mg orodispersible tablets ABILIFY 15 mg orodispersible tablets ABILIFY 30 mg orodispersible tablets aripiprazole 
Uputa o lijeku: Informacije za korisnika ABILIFY 10 mg raspadljive tablete za usta ABILIFY 15 mg raspadljive tablete za usta ABILIFY 30 mg raspadljive tablete za usta aripiprazol
If you are given more ABILIFY than you need 
Ako primite više lijeka ABILIFY nego što ste trebali
All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to 
Sve nuspojave navedene su prema klasifikaciji organskih sustava i učestalosti; vrlo često (≥ 1/10),
• The other ingredients are sulfobutylether β-cyclodextrin (SBECD), tartaric acid, sodium hydroxide, and water for injections. 
• Drugi sastojci su sulfobutileter β-ciklodekstrin (SBECD), tartaratna kiselina, natrijev hidroksid i voda za injekcije.
Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Åsberg Depression Rating Scale (MADRS) showed a significant improvement over haloperidol. 
Montgomery-Åsberg-Depression-Rating-Scale, MADRS], koji su se koristili kao sekundarne mjere ishoda, pokazali su značajno poboljšanje u odnosu na haloperidol.
Also contains: lactose monohydrate. 
POPIS POMOĆNIH TVARI Također sadrži: laktozu hidrat.
However, in a single-dose, intramuscular study of aripiprazole (dose 15 mg) in healthy subjects, administered simultaneously with intramuscular lorazepam (dose 2 mg), the orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone. 
Međutim, u ispitivanju jednokratne intramuskularne doze aripiprazola (od 15 mg) primijenjene istodobno s intramuskularnim lorazepamom (u dozi od 2 mg) u zdravih ispitanika, opažena ortostatska hipotenzija bila je veća uz kombinaciju tih lijekova nego kad se lorazepam primijenio sam.
The administration of ABILIFY solution for injection had no effect on the pharmacokinetics of lorazepam solution for injection when administered concomitantly. 
Primjena ABILIFY otopine za injekciju nije imala učinka na farmakokinetiku lorazepam otopine za injekciju prilikom istodobne primjene.
In a 26-week, olanzapine-controlled, double-blind, multi-national study of schizophrenia which included 314 adult patients and where the primary endpoint was weight gain, significantly less patients had at least 7 % weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on aripiprazole (n = 18, or 13 % of evaluable patients), compared to olanzapine (n = 45, or 33 % of evaluable patients). 
U 26-tjednom, olanzapinom kontroliranom, dvostruko slijepom, multinacionalnom ispitivanju shizofrenije koje je uključilo 314 odraslih bolesnika i gdje je primarna mjera ishoda bilo povećanje tjelesne težine, značajno manje bolesnika imalo je povećanje tjelesne težine od najmanje 7 % u odnosu na početnu vrijednost (tj. prirast od najmanje 5,6 kg na prosječnu početnu težinu od ~80,5 kg) u skupini na aripiprazolu (n = 18, ili 13 % bolesnika koji su se mogli procijeniti) u usporedbi sa skupinom koja je uzimala olanzapin (n = 45, ili 33 % bolesnika koji su se mogli procijeniti).
The correct amount of solution will be injected into your muscle by your doctor or nurse. 
Liječnik ili medicinska sestra će vam dati ispravnu dozu otopine injekcijom u mišić.
• involuntary loss of urine (incontinence), 
• nemogućnost kontroliranja mokrenja (inkontinencija),
Package leaflet: Information for the user ABILIFY 7.5 mg/mL solution for injection aripiprazole 
Uputa o lijeku: Informacije za korisnika ABILIFY 7,5 mg/ml otopina za injekciju aripiprazol
Upon discontinuation of strong CYP3A4 inducers, the dosage of aripiprazole should be reduced to the recommended dose. 
Nakon prekida primjene jakih induktora CYP3A4, dozu aripiprazola potrebno je smanjiti na preporučenu dozu.
ABILIFY contains parahydroxybenzoates 
ABILIFY sadrži parahidroksibenzoat
• inflammation of the liver, 
• zatajenje jetre,
The following adverse reactions had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1 %; 30 mg, 28.8 %; placebo, 1.7 %); and akathisia (incidences were 10 mg, 12.1 %; 30 mg, 20.3 %; placebo, 1.7 %). 
(incidencija je bila 9,1 % za dozu od 10 mg; 28,8 % za dozu od 30 mg i 1,7 % za placebo) i akatizija (incidencija je bila 12,1 % za dozu od 10 mg; 20,3 % za dozu od 30 mg i 1,7 % za placebo).
• double vision, 
• dvoslike,
In contrast the 95 % confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients. 
Nasuprot tome, 95%-tni interval pouzdanosti za HR u starijoj podskupini (aripiprazol, n = 69; placebo, n = 36) iznosio je 0,242 do
ABILIFY 5 mg tablets ABILIFY 10 mg tablets ABILIFY 15 mg tablets ABILIFY 30 mg tablets 
ABILIFY 5 mg tablete ABILIFY 10 mg tablete ABILIFY 15 mg tablete ABILIFY 30 mg tablete
ABILIFY 5 mg tablets Indigo carmine aluminium lake (E 132) 
ABILIFY 5 mg tablete Boja Indigo carmine aluminium lake (E 132) ABILIFY 10 mg tablete
The AUC and Cmax of dehydroaripiprazole increased by 77 % and 43 %, respectively. 
AUC dehidro-aripiprazola povisio se za 77 %, a Cmax za 43 %.
The overall completion rate was significantly higher for patients on oral aripiprazole (43 %) than for oral haloperidol (30 %). 
Ukupna stopa dovršetka ispitivanja bila je značajno viša u skupini bolesnika koji su uzimali oralni aripiprazol (43 %) nego u onih na oralnom haloperidolu (30 %).
No dosage adjustment is required for patients with mild to moderate hepatic impairment. 
Nije potrebno prilagođivati dozu u bolesnika s blagim do umjerenim oštećenjem funkcije jetre.
14 × 1 orodispersible tablets 28 × 1 orodispersible tablets 49 × 1 orodispersible tablets 
14 × 1 raspadljiva tableta za usta 28 × 1 raspadljiva tableta za usta 49 × 1 raspadljiva tableta za usta
ABILIFY 5 mg tablets ABILIFY 10 mg tablets ABILIFY 15 mg tablets ABILIFY 30 mg tablets aripiprazole 
ABILIFY 5 mg tablete ABILIFY 10 mg tablete ABILIFY 15 mg tablete ABILIFY 30 mg tablete aripiprazol
Population pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of clinically relevant effects from smoking on the pharmacokinetics of aripiprazole. 
Populacijska farmakokinetička procjena oralnog aripiprazola nije otkrila nikakve dokaze klinički važnih učinaka pušenja na farmakokinetiku aripiprazola.
The efficacy of ABILIFY solution for injection in patients with agitation and disturbed behaviours has not been established related to conditions other than schizophrenia and manic episodes in Bipolar I Disorder. 
Nije utvrđena djelotvornost ABILIFY otopine za injekciju u bolesnika s agitacijom i poremećenim ponašanjem uzrokovanim stanjima različitim od shizofrenije i maničnih epizoda u sklopu bipolarnog poremećaja tipa I.
In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1). 
U kliničkim ispitivanjima u odobrenim indikacijama i nakon stavljanja lijeka u promet, opaženo je i povećanje i smanjenje prolaktina u serumu uz aripiprazol u usporedbi s početim vrijednostima
The mean weight gain over the stabilisation phase (up to 26 weeks) on aripiprazole was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for placebo was observed in the second phase (16 weeks) of the trial. 
(najviše 26 tjedana) u ispitanika na aripiprazolu iznosilo je 3,2 kg, a u drugoj fazi ispitivanja (16 tjedana) zabilježeno je dodatno srednje povećanje od 2,2 kg u usporedbi s 0,6 kg u bolesnika koji su primali placebo.
There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. 
Prijavljeni su agitacija, hipertonija, hipotonija, tremor,
A vial provides 9.75 mg in 1.3 mL. 
Jedna bočica sadrži 9,75 mg u 1,3 ml.
Schizophrenia: in a long-term 52-week controlled trial, aripiprazole-treated patients had an overalllower incidence (25.8 %) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %). 
Shizofrenija: u dugotrajnom kontroliranom ispitivanju u trajanju od 52 tjedna, bolesnici liječeni aripiprazolom imali su nižu ukupnu incidenciju (25,8 %) EPS-a uključujući parkinsonizam, akatiziju,